In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioDebt: Wooing the Lower-Risk Investor

Executive Summary

Biotech companies suffer under a financing handicap: they can only attract high-risk equity investors. Now a few companies, albeit with products on the market or nearly so, are borrowing money and, along with interest, paying investors royalties on product sales. They're looking to tap into a group of investors with a lower appetite for risk but who require something more from unproven companies than just a standard interest rate.

You may also be interested in...



Terrorism's Impact on the Drug Industry

Terrorism has lowered investors' tolerance for risk. Investors aren't willing to accept as they have in the past the traditional uncertainties of biopharmaceutical investing. Instead, they are looking for companies that understand how to manage all risk, starting with technology and extending into partnering potential, the regulatory arena, and the marketplace. Beyond these visible dangers lies a subtle one: the societal risk posed by the drug industry's aggressive pricing strategies.

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel